Stock of the Day for October 24, 2024

Merck & Co., Inc. Stock Report

Merck & Co., Inc.
MRK 90-day performance NYSE:MRK Merck & Co., Inc.
Current Price
$82.87
-2.28 (-2.68%)
(As of 09/12/2025 03:59 PM ET)
30 Day Performance
-1.75%
  
  
90 Day Performance
5.75%
  
 
1 Year Performance
-28.47%
  
  
Market Capitalization
$206.99B
P/E Ratio
12.77
Dividend Yield
3.91%

About Merck & Co., Inc.

Merck & Co., Inc. (NYSE: MRK) is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of a broad range of innovative human and animal health products. The company’s human health portfolio spans oncology, vaccines, infectious diseases, cardio-metabolic disorders and hospital acute care, with leading prescription medicines including Keytruda® for cancer immunotherapy, Gardasil® for HPV-related diseases and Januvia® for type 2 diabetes. In its animal health division, Merck provides vaccines and pharmaceutical therapies for livestock and companion animals, addressing conditions from parasitic infestations to respiratory and reproductive diseases.

Merck traces its origins to 1891 when George W. Merck established a U.S. affiliate of the German Merck company. The modern corporation took shape following World War I and has since grown through research breakthroughs and strategic acquisitions to become one of the world’s largest pharmaceutical companies. Its research and development efforts are supported by a global network of laboratories and manufacturing facilities, with major R&D centers in the United States, Europe and Asia.

Headquartered in Kenilworth, New Jersey, Merck operates in more than 140 countries, serving patients, healthcare professionals and animal health customers worldwide. The company maintains partnerships with academic institutions, government agencies and other biopharma organizations to advance scientific understanding and accelerate the delivery of novel therapies. Merck is committed to expanding access to its medicines and vaccines through pricing programs, licensing agreements and support for healthcare infrastructure in underserved regions.

Under the leadership of Chairman and Chief Executive Officer Robert M. Davis, Merck continues to invest in cutting-edge technologies such as mRNA platforms, cell and gene therapy, and next-generation oncology targets. The company’s mission is to translate innovative science into medicines and vaccines that help people and communities around the world.

MRK Company Calendar

JUN. 16, 2025
Ex-Dividend for 7/8 Dividend
JUL. 8, 2025
Dividend Payable
JUL. 29, 2025
Last Earnings
SEP. 15, 2025
Today
SEP. 15, 2025
Ex-Dividend for 10/7 Dividend
OCT. 7, 2025
Dividend Payable
OCT. 30, 2025
Next Earnings (Estimated)
DEC. 31, 2025
Fiscal Year End

Recent Merck & Co., Inc. News

2 Healthcare Dividend Stocks to Buy and Hold
Swedbank AB Has $717 Million Stake in Merck & Co., Inc. $MRK
Wealth Alliance Advisory Group LLC Grows Stock Holdings in Merck & Co., Inc. $MRK
Wesbanco Bank Inc. Sells 4,855 Shares of Merck & Co., Inc. $MRK
Bontempo Ohly Capital Mgmt LLC Invests $4 Million in Merck & Co., Inc. $MRK
Hodges Capital Management Inc. Acquires 14,428 Shares of Merck & Co., Inc. $MRK
OMNI 360 Wealth Inc. Has $749,000 Stake in Merck & Co., Inc. $MRK
Salem Investment Counselors Inc. Cuts Stock Holdings in Merck & Co., Inc. $MRK
This report was written by MarketBeat.com on September 15, 2025. This report first appeared on MarketBeat.com.